ASH 2023: Exploring Therapeutic Advancements for Chronic Lymphocytic Leukemia - Episode 4

Impact of Off-Target AEs and Treatment Resistance on Evolving 1L Therapy Strategies for CLL

, , , , ,

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.